R. K. Jain. Delivery of molecular medicine to solid tumors. Science 271:1079–1080 (1996).
E. Harper, W. Dang, R. G. Lapidus, and R. I. Garver, Jr. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local–regional therapy of lung cancer tumor nodules in mice. Clin. Cancer Res. 5:4242–4248 (1999).
P. A. Vasey, S. B. Kaye, R. Morrison, C. Twelves, P. Wilson, R. Duncan, A. H. Thomson, L. S. Murray, T. E. Hilditch, T. Murray, S. Burtles, D. Fraier, E. Frigerio, and J. Cassidy. Phase I clinical and pharmacokinetic study of PK1 [N–(2–hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents–drug–polymer conjugates. Clin. Cancer Res. 5:83–94 (1999).
G. P. Adams. Improving the tumor specificity and retention of antibody–based molecules. In Vivo 12:11–21 (1998).
S. R. Schwarze, A. Ho, A. VoceroAkbani, and S. F. Dowdy. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285:1569–1572 (1999).
G. Pagnan, D. D. Stuart, F. Pastorino, L. Raffaghello, P. G. Montaldo, T. M. Allen, B. Calabretta, and M. Ponzoni. Delivery of c–myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)–targeted immunoliposomes: antitumor effects. J. Natl. Cancer Inst. 92:253–261 (2000).
J. K. Wolf, G. B. Mills, L. Bazzet, R. C. Bast Jr., J. A. Roth, and D. M. Gershenson. Adenovirus–mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. Gynecol. Oncol. 75:261–266 (1999).
F. M. Muggia. Doxorubicin–polymer conjugates: further demonstration of the concept of enhanced permeability and retention. Clin. Cancer Res. 5:7–8 (1999).
R. K. Jain. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J. Natl. Cancer Inst. 81:570–576 (1989).
H. P. Buscher. Defective drug uptake contributing to multidrug resistance in hepatoma cells can be evaluated in vitro. Klin. Wochenschr. 68:443–446 (1990).
D. J. Taatjes and T. H. Koch. Nuclear targeting and retention of anthracycline antitumor drugs in sensitive and resistant tumor cells. Curr. Med. Chem. 8:15–29 (2001).
K. Maruyama. In vivo targeting by liposomes. Biol. Pharm. Bull. 23:791–799 (2000).
L. D. Mayer. Future developments in the specificity of anticancer agents: drug delivery and molecular target. Cancer Metastasis Rev. 17:211–218 (1998).
G. Molema, D. K. Meijer, and L. F. de Leij. Tumor vasculature targeted therapies: getting the players organized. Biochem. Pharmacol. 55:1939–1945 (1998).
J. Sudimack and R. J. Lee. Targeted drug delivery via the folate receptor. Adv. Drug Del. Rev. 41:147–162 (2000).
R. K. Jain. Determinants of tumor blood flow: a review. Cancer Res. 48:2641–2658 (1988).
S. A. Skinner, G. M. Frydman, and P. E. O'Brien. Microvascular structure of benign and malignant tumors of the colon in humans. Dig. Dis. Sci. 40:373–384 (1995).
J. Folkman. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82:4–6 (1990).
L. A. Liotta, J. Kleinerman, and G. M. Saidel. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res. 34:997–1004 (1974).
J. Folkman. Tumor angiogenesis. In P. M. Mendelsohn, M. A. P. Howley, and L. A. Liotta (eds.), The Molecular Basis of Cancer, W.B. Saunders, Philadelphia, Pennsylvania, 1995 pp. 206–232.
P. Shubik. Vascularization of tumors: a review. J. Cancer Res. Clin. Oncol. 103:211–226 (1982).
H. Yamaura and H. Sato. Quantitative studies on the developing vascular system of rat hepatoma. J. Natl. Cancer Inst. 53:1229–1240 (1974).
P. Rubin and G. Casarett. Microcirculation of tumors. I. Anatomy, function, and necrosis. Clin. Radiol. 17:220–229 (1966).
S. Lauk, A. Zietman, S. Skates, R. Fabian, and H. D. Suit. Comparative morphometric study of tumor vasculature in human squamous cell carcinomas and their xenotransplants in athymic nude mice. Cancer Res. 49:4557–4561 (1989).
P. Falk. Differences in vascular pattern between the spontaneous and the transplanted C3H mouse mammary carcinomau. Eur. J. Cancer Clin. Oncol. 18:155–165 (1982).
M. Leunig, F. Yuan, M. D. Menger, Y. Boucher, A. E. Goetz, K. Messmer, and R. K. Jain. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res. 52:6553–6560 (1992).
Y. Boucher, M. Leunig, and R. K. Jain. Tumor angiogenesis and interstitial hypertension. Cancer Res. 56:4264–4266 (1996).
B. Endrich, H. S. Reinhold, J. F. Gross, and M. Intaglietta. Tissue perfusion inhomogeneity during early tumor growth in ratsy. J. Natl. Cancer Inst. 62:387–395 (1979).
R. K. Jain and K. A. Ward–Hartley. Tumor blood flow — characterization, modification, and role in hyperthermia. IEEE Trans. Sonics Ultrasonics 31:504–526 (1984).
S. A. Skinner, P. J. Tutton, and P. E. O'Brien. Microvascular architecture of experimental colon tumors in the rat. Cancer Res. 50:2411–2417 (1990).
I. F. Tannock and G. G. Steel. Quantitative techniques for study of the anatomy and function of small blood vessels in tumors. J. Natl. Cancer Inst. 42:771–782 (1969).
L. S. Heuser and F. N. Miller. Differential macromolecular leakage from the vasculature of tumors. Cancer 57:461–464 (1986).
K. Hori, M. Suzuki, S. Tanda, and S. Saito. In vivo analysis of tumor vascularization in the rat. Jpn. J. Cancer Res. 81:279–288 (1990).
F. Yuan, M. Leunig, S. K. Huang, D. A. Berk, D. Papahadjopoulos, and R. K. Jain. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54:3352–3356 (1994).
F. Yuan, H. A. Salehi, Y. Boucher, U. S. Vasthare, R. F. Tuma, and R. K. Jain. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res. 54:4564–4568 (1994).
S. K. Hobbs, W. L. Monsky, F. Yuan, W. G. Roberts, L. Griffith, V. P. Torchilin and R. K. Jain. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA 95:4607–4612 (1998).
M. Bundgaard. Transport pathways in capillaries — in search of pores. Annu. Rev. Physiol. 42:325–336 (1980).
N. Simionescu, M. Simionescu, and G. E. Palade. Open junctions in the endothelium of the postcapillary venules of the diaphragm. J. Cell Biol. 79:27–44 (1978).
J. C. Firrell, G. P. Lewis, and L. J. Youlten. Vascular permeability to macromolecules in rabbit paw and skeletal muscle: a lymphatic study with a mathematical interpretation of transport processes. Microvasc. Res. 23:294–310 (1982).
L. W. Seymour. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit. Rev. Ther. Drug Carrier Syst. 9:135–187 (1992).
H. Lum and A. B. Malik. Regulation of vascular endothelial barrier function. Am. J. Physiol. 267:L223–L241 (1994).
D. R. Senger, S. J. Galli, A. M. Dvorak, C. A. Perruzzi, V. S. Harvey, and H. F. Dvorak. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983–985 (1983).
P. D. Collins, D. T. Connolly, and T. J. Williams. Characterization of the increase in vascular permeability induced by vascular permeability factor in vivo. Br. J. Pharmacol. 109:195–199 (1993).
W. G. Roberts and G. E. Palade. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell Sci. 108:2369–2379 (1995).
D. W. Leung, G. Cachianes, W. J. Kuang, D. V. Goeddel, and N. Ferrara. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306–1309 (1989).
M. Dellian, B. P. Witwer, H. A. Salehi, F. Yuan, and R. K. Jain. Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. Am. J. Pathol. 149:59–71 (1996).
H. Maeda, Y. Matsumura, and H. Kato. Purification and identification of [hydroxyprolyl3]bradykinin in ascitic fluid from a patient with gastric cancer. J. Biol. Chem. 263:16051–16054 (1988).
Y. Matsumura, M. Kimura, T. Yamamoto, and H. Maeda. Involvement of the kinin–generating cascade in enhanced vascular permeability in tumor tissue. Jpn. J. Cancer Res. 79:1327–1334 (1988).
J. Wu, T. Akaike, and H. Maeda. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res. 58:159–165 (1998).
W. Peters, M. Teixeira, M. Intaglietta, and I. F. Gross. Microcirculatory studies in a rat mammary carcinoma. I. Transparent chamber method, development of microvasculature and pressures in tumor vessels. J. Natl. Cancer Inst. 65:631–642 (1980).
K. Hori, M. Suzuki, S. Tanda, and S. Saito. Characterization of heterogeneous distribution of tumor blood flow in the rat. Jpn. J. Cancer Res. 82:109–117 (1991).
J. Straw, M. Hart, P. Klubes, D. Zaharko, and R. L. Dedrick. Distribution of anticancer agents in spontaneous animal tumors. I. Regional blood flow and methotrexate distribution in canine lymphosarcoma. J. Natl. Cancer Inst. 52:1327–1331 (1974).
R. P. Beaney, A. A. Lammertsma, T. Jones, C. G. McKenzie, and K. E. Halnan. In vivo measurements of regional blood flow, oxygen utilization and blood volume in patients with carcinoma of the breast using positron tomography. Lancet 1:131–134 (1984).
R. K. Jain. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 50:814s–819s (1990).
J. H. Ackerman, C. S. Ewy, N. N. Becker, and R. A. Shalwitz. Deuterium Nuclear Magnetic Resonance Measurements of Blood Flow and Tissue Perfusion Employing 2H2O as a Freely Diffusible Tracer. Proc. Natl. Acad. Sci. USA 84:4099–4102 (1987).
J. L. Evelhoch. Measurement of tumor blood flow by deuterium NMR and the effects of modifiers. NMR Biomed. 5:290–295 (1992).
L. Bogin, R. Margalit, H. Ristau, J. Mispelter, and H. Degani. Parametric imaging of tumor perfusion with deuterium magnetic resonance imaging. Microvasc. Res. 64:104–115 (2002)
S. P. Robinson, F. A. Howe, and J. R. Griffiths. Noninvasive monitoring of carbogen–induced changes in tumor blood flow and oxygenation by functional magnetic resonance imaging. Int. J. Radiat. Oncol. Biol. Phys. 33:855–859 (1995).
S. P. Robinson, F. A. Howe, L. M. Rodrigues, M. Stubbs, and J. R. Griffiths. Magnetic resonance imaging techniques for monitoring changes in tumor oxygenation and blood flow. Semin. Radiat. Oncol. 8:197–207 (1998).
M. H. Lev and F. Hochberg. Perfusion magnetic imaging to assess brain tumor responses to new therapies. Cancer Control 5:115–123 (1998).
T. F. Logan, F. Jadali, M. J. Egorin, M. Mintun, D. Sashin, W. E. Gooding, Y. Choi, H. Bishop, D. L. Trump, D. Gardner, J. Kirkwood, D. Vlock, and C. Johnson. Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin–1 and carboplatin on a phase I trial. Cancer Chemother. Pharmacol. 50:433–444 (2002).
H. Anderson and P. Price. Clinical measurement of blood flow in tumours using positron emission tomography: a review. Nucl. Med. Commun. 23:131–138 (2002).
S. L. Bacharach, S. K. Libutti, and J. A. Carrasquillo. Measuring tumor blood flow with H2
15O: practical considerations. Nucl. Med. Biol. 27:671–676 (2000).
P. N. Burns. Interpreting and analyzing the Doppler examination. In K. J. W. Taylor, P. N. Burns, and P. N. T. Wells (eds.), Clinical Applications of Doppler Ultrasound, Raven, New York, 1995, pp. 55–98.
P. N. T. Wells. Basic principles and Doppler physics. In K. J. W. Taylor, P. N. Burns, and P. N. T. Wells (eds.), Clinical Applications of Doppler Ultrasound, Raven, New York, 1995, pp. 1–17.
D. E. Goertz, J. L. Yu, R. S. Kerbel, P. N. Burns, and F. S. Foster. High–frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Res. 62:6371–6375 (2002).
C. Peters–Engl, W. Frank, S. Leodolter, and M. Medl. Tumor flow in malignant breast tumors measured by Doppler ultrasound: an independent predictor of survival. Breast Cancer Res. Treat. 54:65–71 (1999).
K. Okihara, H. Watanabe, and M. Kojima. Kinetic study of tumor blood flow in prostatic cancer using power Doppler imaging. Ultrasoud Med. Biol. 25:89–94 (1999).
A. Iwamaru, M. Watanabe, S. Yu, T. Ohtsuka, H. Horinouchi, and K. Kobayashi. Measurement of tumor blood flow using colored dye extraction microspheres in two rat tumor models. Int. J. Oncolology 18:227–232 (2001).
A. Sckell, N. Safabakhsh, M. Dellian, and R. K. Jain. Primary tumor size–dependent inhibition of angiogenesis at a secondary site: an intravital microscopic study in mice. Cancer Res. 58:5866–5869 (1998).
H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65:271–284 (2000).
C. M. O'Driscoll. Anatomy and physiology of the lymphatics. In W. N. Charman and V. J. Stella (eds.), Lymphatic Transport of Drugs, CRC Press, Boca Raton, Florida, 1992, pp. 1–36.
R. K. Jain. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 6:559–593 (1987).
D. C. Drummond, O. Meyer, K. Hong, D. B. Kirpotin, and D. Papahadjopoulos. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51:691–743 (1999).
Y. Matsumura and H. Maeda. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46:6387–6392 (1986).
K. Iwai, H. Maeda, and T. Konno. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X–ray image. Cancer Res. 44:2115–2121 (1984).
Y. Noguchi, J. Wu, R. Duncan, J. Strohalm, K. Ulbrich, T. Akaike, and H. Maeda. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 89:307–314 (1998).
F. M. Muggia. Doxorubicin–polymer conjugates: further demonstration of the concept of enhanced permeability and retention. Clin. Cancer Res. 5:7–8 (1999).
L. W. Seymour, K. Ulbrich, P. S. Steyger, M. Brereton, V. Subr, J. Strohalm, and R. Duncan. Tumour tropism and anti–cancer efficacy of polymer–based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer 70:636–641 (1994).
H. Maeda. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor–selective macromolecular drug targeting. Adv. Enzyme Regul. 41:189–207 (2001).
H. Maeda. SMANCS and polymer–conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 46:169–185 (2001).
H. Sinn, H. H. Schrenk, E. A. Friedrich, U. Schilling, and W. Maier–Borst. Design of compounds having an enhanced tumour uptake, using serum albumin as a carrier. Part I. Int. J. Rad. Appl. Instrum. 17:819–827 (1990).
N. Z. Wu, D. Da, T. L. Rudoll, D. Needham, A. R. Whorton, and M. W. Dewhirst. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res. 53:3765–3770 (1993).
D. W. Northfelt, F. J. Martin, P. Working, P. A. Volberding, J. Russell, M. Newman, M. A. Amantea, and L. D. Kaplan. Doxorubicin encapsulated in liposomes containing surface–bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS–related Kaposi's sarcoma. J. Clin. Pharamcol. 36:55–63 (1996).
R. K. Jain. Transport of molecules in the tumor interstitium: a review. Cancer Res. 47:3039–3051 (1987).
Y. Boucher and R. K. Jain. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res. 52:5110–5114 (1992).
L. T. Baxter and R. K. Jain. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Microvasc. Res. 37:77–104 (1989).
R. Duncan and Y. N. Sat. Tumor targeting by enhanced permeability and retention (EPR) effect. Ann. Oncol. 9:39(1998).
R. K. Jain. Transport phenomena in tumors. Adv. Chem. Eng. 19:129–200 (1994).
J. R. Less, T. C. Skalak, E. M. Sevick, and R. K. Jain. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res. 51:265–273 (1991).
H. K. Awwad, M. el Naggar, N. Mocktar, and M. Barsoum. Intercapillary distance measurement as an indicator of hypoxia in carcinoma of the cervix uteri. Int. J. Radiation Oncology Biol. Phys. 12:1329–1333 (1986).
P. Vaupel. Hypoxia in neoplastic tissue. Microvas. Res. 13:399–408 (1977).
T. Sasaki, M. Yamamoto, T. Yamaguchi, and S. Sugiyama. Development of multicellular spheroids of HeLa cells cocultured with fibroblasts and their response to X–irradiation. Cancer Res. 44:345–351 (1984).
R. M. Sutherland and R. E. Durand. Radiation response of multicell spheroids–an in vitro tumour model. Curr. Top. Radiat. Res. 11:87–139 (1976).
R. E. Durand. Variable radiobiological responses of spheroids. Radiat. Res. 81:85–99 (1980).
R. E. Durand. Chemosensitivity testing in V79 spheroids: drug delivery and cellular microenvironment. J. Natl. Cancer Inst. 77:247–252 (1986).
J. Carlsson, K. Nilsson, B. Westermark, J. Ponten, C. Sundstrom, E. Larsson, J. Bergh, S. Pahlman, C. Busch, and V. P. Collins. Formation and growth of multicellular spheroids of human origin. Int. J. Cancer 31:523–533 1983).
T. Nederman, B. Norling, B. Glimelius, J. Carlsson, and U. Brunk. Demonstration of an extracellular matrix in multicellular tumor spheroids. Cancer Res. 44:3090–3097 (1984).
T. Nederman and J. Carlsson. Penetration and binding of vinblastine and 5–fluorouracil in cellular spheroids. Cancer Chemother. Pharmacol. 13:131–135 (1984).
T. Nederman, J. Carlsson, and K. Kuoppa. Penetration of substances into tumour tissue. Model studies using saccharides, thymidine and thymidine–5′–triphosphate in cellular spheroids. Cancer Chemother. Pharmacol. 22:21–25 (1988).
C. Erlichman and D. Vidgen. Cytotoxicity of adriamycin in MGH–U1 cells grown as monolayer cultures, spheroids, and xenografts in immune–deprived mice. Cancer Res. 44:5369–5375 (1984).
M. Erlanson, E. Daniel–Szolgay, and J. Carlsson. Relations between the penetration, binding and average concentration of cytostatic drugs in human tumour spheroids. Cancer Chemother. Pharmacol. 29:343–353 (1992).
R. E. Durand. Slow penetration of anthracyclines into spheroids and tumors: a therapeutic advantage? Cancer Chemother. Pharmacol. 26:198–204 (1990).
G. W. West, R. Weichselbaum, and J. B. Little. Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res. 40:3665–3668 (1980).
K. M. Nicholson, M. C. Bibby, and R. M. Phillips. Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids. Eur. J. Cancer 33:1291–1298 (1997).
P. M. Gullino and F. H. Grantham. The influence of the host and the neoplastic cell population on the collagen content of a tumor mass. Cancer Res. 23:648–653 (1963).
C. P. Winlove and K. H. Parker. The physiological function of the extracellular matrix. In R. K. Reed, G. A. Laine, J. L. Bert, C. P. Winlove, and N. McHale (eds.), Interstitium, Connective Tissue and Lymphatics, Portland Press, London, 1995, pp. 137–165.
L. A. Liotta and C. N. Rao. Role of the extracellular matrix in cancer. Ann. NY Acad. Sci. 460:333–344 (1985).
K. Aukland and G. Nicolaysen. Interstitial fluid volume: local regulatory mechanisms. Physiol. Rev. 61:556–643 (1981).
G. W. Jackson and D. F. James. The hydrodynamic resistance of hyaluronic acid and its contribution to tissue permeability. Biorheology 19:317–330 (1982).
J. R. Levick. Relation between hydraulic resistance and composition of the interstitium. In N. C. Staub, J. C. Hogg, and A. R. Hargens (eds.), Interstitial–Lymphatic Liquid and Solute Movement, Karger, New York, 1987, pp. 124–133.
R. H. Pearce. Glycosaminoglycans and glycoproteins in skin. In E. A. Balazs and R. W. Jeanloz (eds.), The Amino Sugars, Academic Press, New York, 1965, pp. 149–193.
Z. Brada. Host–tumor relationship. XX. The hexosamine content and the tumor as a marker of relation between the tumor stroma and tumor cells. Neoplasma (Bratisl) 12:373–378 (1965).
B. Sylven. Amino–sugar containing compounds in tumors. In E. A. Balazs and R. W. Jeanloz (eds.), The Amino Sugars, Academic Press, New York, 1965, pp. 195–204.
P. A. Netti, D. A. Berk, M. A. Swartz, A. J. Grodzinsky, and R. K. Jain. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 60:2497–2503 (2000).
A. Pluen, S. Ramanujan, Y. Boucher, E. Unemori, B. Seed, and R. K. Jain. Relaxin increases the transport of large molecules in high collagen content tumors. Proc. Am. Assoc. Cancer Res. 38:604(2000).
J. R. Fox and H. Wayland. Interstitial diffusion of macromolecules in the rat mesentery. Microvasc. Res. 18:255–276 (1979).
J. S. Schultz and W. Armstrong. Permeability of interstitial space of muscle (rat diaphragm) to solutes of different molecular weights. J. Pharm. Sci. 67:696–700 (1978).
H. J. Kuh, S. H. Jang, M. G. Wientjes, J. R. Weaver, and J. L.–S. Au. Determinants of paclitaxel penetration and accumulation in human solid tumor. J. Pharmacol. Exp. Ther. 290:871–880 (1999).
S. H. Jang, M. G. Wientjes, and J. L.–S. Au. Enhancement of paclitaxel delivery to solid tumors by apoptosis–inducing pretreatment: Effect of treatment schedule. J. Pharmacol. Exp. Ther. 296:1035–1042 (2001).
J. H. Zheng, C. T. Chen, J. L.–S. Au, and M. G. Wientjes. Time–and concentration–dependent penetration of doxorubicin in prostate tumors. AAPS PharmSci. 3:article 15(2001) (http://www.pharmsci.org/journal)
K. T. Robbins, K. M. Connors, A. M. Storniolo, C. Hanchett, and R. M. Hoffman. Sponge–gel–supported histoculture drug–response assay for head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 120:288–292 (1994).
T. Furukawa, T. Kubota, and R. M. Hoffman. The clinical applications of the histoculture drug response assay. Clin. Cancer Res. 1:305–311 (1995).
R. S. Kerbel. Tumor angiogenesis: past, present and the near future. Carcinogenesis 21:505–515 (2000).
J. L.–S. Au, N. Panchal, D. Li, and Y. Gan. Apoptosis: a new pharmacodynamic endpoint. Pharm. Res. 14:1659–1671 (1997)
J. L.–S. Au, D. Li, Y. Gan, X. Gao, A. L. Johnson, J. Johnston, N. J. Millenbaugh, S. H. Jang, H. J. Kuh, C. T. Chen, and M. G. Wientjes. Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. Cancer Res. 58:2141–2148 (1998).
L. Cheng, S. Zheng, K. Raghunathan, D. G. Priest, M. C. Willingham, J. S. Norris, and W. Fan. Characterisations of taxol–induced apoptosis and altered gene expression in human breast cancer cells. Cell. Pharmacol. 2:249–257 (1995).
L. Milas, N. R. Hunter, B. Kurdoglu, K. A. Mason, R. E. Meyn, L. C. Stephens, and L. J. Peters. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother. Pharmacol. 35:297–303 (1995).
D. E. Saunders, W. D. Lawrence, C. Christensen, N. L. Wappler, H. Ruan, and G. Deppe. Paclitaxel–induced apoptosis in MCF7 breast cancer cells. Int. J. Cancer 70:214–220 (1997).
Y. Gan, M. G. Wientjes, D. E. Schuller, and J. L.–S. Au. Pharmacodynamics of taxol in human head and neck tumors. Cancer Res. 56:2086–2093 (1996).
J. L.–S. Au, R. R. Kumar, D. Li, and M. G. Wientjes. Kinetics of hallmark biochemical changes in paclitaxel–induced apoptosis. AAPS PharmSci. 1:article 8. (1999) (http://www.pharmsci.org/journal)
C. T. Chen, J. L.–S. Au, and M. G. Wientjes. Pharmacodynamics of doxorubicin in human prostate tumors. Clin. Cancer Res. 4:227–282 (1998).
P. Nicotera, M. Leist, and E. Ferrando–May. Apoptosis and necrosis: different execution of the same death. Biochem. Soc. Symp. 66:69–73 (1999).
D. Kanduc, A. Mittelman, R. Serpico, E. Sinigaglia, A. Sinha, C. Natale, R. Santacroce, C. Di, A. Lucchese, L. Dini, P. Pani, S. Santacroce, S. Simone, R. Bucci, and E. Farber. Cell death: Apoptosis versus necrosis (Review). Int. J. Oncology 21:165–170 (2002).
S. Kinuya, K. Yokoyama, T. Hiramatsu, H. Tega, K. Tanaka, S. Konishi, N. Shuke, T. Aburano, N. Watanabe, T. Takayama, T. Michigishi, and N. Tonami. Combination radioimmunotherapy with local hyperthermia: increased delivery of radioimmunoconjugate by vascular effect and its retention by increased antigen expression in colon cancer xenografts. Cancer Lett. 140:209–218 (1999).
J. M. Schuster, M. R. Zalutsky, M. A. Noska, R. Dodge, H. S. Friedman, D. D. Bigner, and M. W. Dewhirst. Hyperthermic modulation of radiolabelled antibody uptake in a human glioma xenograft and normal tissues. Int. J. Hyperthermia 11:59–72 (1995).
R. B. Wilder, V. K. Langmuir, H. L. Mendonca, M. L. Goris, and S. J. Knox. Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts. Cancer Res. 53:3022–3027 (1993).
D. S. Gridley, K. L. Ewart, J. D. Cao, and D. R. Stickney. Hyperthermia enhances localization of 111In–labeled hapten to bifunctional antibody in human colon tumor xenografts. Cancer Res. 51:1515–1520 (1991).
D. A. Cope, M. W. Dewhirst, H. S. Friedman, D. D. Bigner, and M. R. Zalutsky. Enhanced delivery of a monoclonal antibody F(ab')2 fragment to subcutaneous human glioma xenografts using local hyperthermia. Cancer Res. 50:1803–1809 (1990).
B. B. Mittal, M. A. Zimmer, V. Sathiaseelan, A. B. Benson iii, R. R. Mittal, S. Dutta, S. T. Rosen, S. M. Spies, J. M. Mettler, and M. W. Groch. Phase I/II trial of combined 131I anti–CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma. Cancer 78:1861–1870 (1996).
B. Endrich and F. Hammersen. Morphologic and hemodynamic alterations in capillaries during hyperthermia. In L. J. Anghileri and J. Robert (eds.), >Hyperthermia in Cancer Treatment, CRC Press, Boca Raton, Florida, 1986 pp. 17–47.
M. Suzuki, K. Hori, I. Abe, S. Saito, and H. Sato. A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J. Natl. Cancer Inst. 67:663–669 (1981).
M. J. Trotter, D. J. Chaplin, and P. L. Olive. Effect of angiotensin II on intermittent tumour blood flow and acute hypoxia in the murine SCCVII carcinoma. Eur. J. Cancer 27:887–893 (1991).
R. F. Edlich, W. Rogers, C. V. DeShazo Jr., and J. B. Aust. Effect of vasoactive drugs on tissue blood flow in the hamster melanoma. Cancer Res. 26:1420–1424 (1966).
K. Hori, Q. H. Zhang, S. Saito, S. Tanda, H. C. Li, and M. Suzuki. Microvascular mechanisms of change in tumor blood flow due to angiotensin II, epinephrine, and methoxamine: a functional morphometric study. Cancer Res. 53:5528–5534 (1993).
I. Abe, K. Hori, S. Saito, S. Tanda, Y. L. Li, and M. Suzuki. Increased intratumor concentration of fluorescein–isothiocyanate–labeled neocarzinostatin in rats under angiotensin–induced hypertension. Jpn. J. Cancer Res. 79:874–879 (1988).
S. A. Al–Merani, D. P. Brooks, B. J. Chapman, and K. A. Munday. The half–lives of angiotensin II, angiotensin II–amide, angiotensin III, Sar1–Ala8–angiotensin II and renin in the circulatory system of the rats. J. Phyasiol. 278:471–490 (1978).
B. J. Chapman, D. P. Brooks, and K. A. Munday. Half–life of angiotensin II in the conscious and barbiturate–anaesthetized rat. Br. J. Anaesth. 52:389–393 (1980).
H. Sato, M. Urushiyama, K. Sugiyama, K. Ishizuka, M. Hoshi, and A. Wakui. Dose intensity and clinical response in patients with advanced gastric carcinoma treated by induced hypertension chemotherapy. Gan To Kagaku Ryoho 17:564–569 (1990).
H. Sato, A. Wakui, M. Hoshi, M. Kurihara, M. Yokoyama, and H. Shimizu. Randomized controlled trial of induced hypertension chemotherapy (IHC) using angiotensin II human (TY–10721) in advanced gastric carcinoma (TY–10721 IHC Study Group Report). Gan To Kagaku Ryoho 18:451–460 (1991).
M. Nakamura, T. Takahashi, H. Sato, M. Hoshi, A. Wakui, and R. Kanamaru. Histopathological evaluation on the effect of induced hypertension chemotherapy presurgically performed in patients with advanced carcinoma of the stomach. Tohoku J. Exp. Med. 167:27–37 (1992).
Z. Zhuand L. Witte. Inhibition of tumor growth and metastasis by targeting tumor–associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest. New Drugs 17:195–212 (1999).
A. Saaristo, T. Karpanen, and K. Alitalo. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 19:6122–6129 (2000).
S. Song, M. G. Wientjes, Y. Gan, and J. L.–S. Au. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc. Natl. Acad. Sci. USA 97:8658–8663 (2000).
S. Song, M. G. Wientjes, C. Walsh, and J. L.–S. Au. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases. Cancer Res. 61:6145–6150 (2001).
Y. Zhang, S. Song, F. Yang, J. L.–S. Au, and M. G. Wientjes. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. J. Pharmacol. Exp. Ther. 299:426–433 (2001).
R. K. Jain. Delivery of molecular and cellular medicine to solid tumors. J. Control. Release 53:49–67 (1998).
P. A. Netti, L. M. Hamberg, J. W. Babich, D. Kierstead, W. Graham, G. J. Hunter, G. L. Wolf, A. Fischman, Y. Boucher, and R. K. Jain. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc. Natl. Acad. Sci. USA 96:3137–3142 (1999).
G. Griffon–Etienne, Y. Boucher, C. Brekken, H. D. Suit, and R. K. Jain. Taxane–induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res. 59:3776–3782 (1999).
K. Hori, M. Suzuki, S. Saito, S. Tanda, Q. H. Zhang, and H. C. Li. Changes in vessel pressure and interstitial fluid pressure of normal subcutis and subcutaneous tumor in rats due to angiotensin II. Microvasc. Res. 48:246–256 (1994).
R. A. Zlotecki, Y. Boucher, I. Lee, L. T. Baxter, and R. K. Jain. Effect of angiotensin II induced hypertension on tumor blood flow and interstitial fluid pressure. Cancer Res. 53:2466–2468 (1993).
R. A. Zlotecki, L. T. Baxter, Y. Boucher, and R. K. Jain. Pharmacologic modification of tumor blood flow and interstitial fluid pressure in a human tumor xenograft: network analysis and mechanistic interpretation. Microvasc. Res. 50:429–443 (1995).
M. Markman, J. Hall, D. Spitz, S. Weiner, L. Carson, L. Van Le, and M. Baker. Phase II trial of weekly single–agent paclitaxel in platinum/paclitaxel–refractory ovarian cancer. J. Clin. Oncol. 20:2365–2369 (2002).
D. Ranney, P. Antich, J. Cohen, W. Erdman, P. Kulkarni, and B. Giovanella. Submillimeter monitoring of tumor–treatment response by contrast–enhanced magnetic resonance imaging (MRI): Implications for tumor access of antibodies lymphokines and macromolecular drugs. Proc. Am. Assoc. Cancer Res. 29:495(1988).
D. F. Ranney. Biomimetic transport and rational drug delivery. Biochem. Pharmacol. 59:105–114 (2000).
R. K. Jain. Understanding barriers to drug delivery: high resolution in vivo imaging is key. Clin. Cancer Res. 5:1605–1606 (1999).